

Zantoral 30mg/ml oral solution for dogs

Authorised

- Ranitidine

Product identification

Medicine name:

Zantoral 30mg/ml oral solution for dogs

Active substance:

Ranitidine

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Ranitidine

30.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Oral solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA02BA02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Luxembourg

Available in:

Luxembourg

Package description:

High density polyethylene bottle 12 ml with high density polyethylene stoppers and a low density polyethylene plug. 3 ml polypropylene/silicone syringe, graduated every 0.1 ml to 3 ml.

High density polyethylene bottle 24 ml with high density polyethylene stoppers and a low density polyethylene plug. 3 ml polypropylene/silicone syringe, graduated every 0.1 ml to 3 ml.

High density polyethylene bottle 48 ml with high density polyethylene stoppers and a low density polyethylene plug. 3 ml polypropylene/silicone syringe, graduated every 0.1 ml to 3 ml.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Emdoka

Marketing authorisation date:

17/04/2024

Manufacturing sites for batch release:

Produlab Pharma B.V.

Responsible authority:

Ministry Of Health And Social Security

Authorisation number:

V 675/17/04/2024

Date of authorisation status change:

17/04/2024

Reference member state:

Italy

Procedure number:

IT/V/0141/001

Concerned member states:

Austria Belgium Germany Luxembourg Netherlands

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents